Department of Epidemiology, Hygiene and Environmental Protection of the State Educational Establishment “Institute of Postgraduate Education in Healthcare of the Republic of Tajikistan” 2State Establishment “Republican Center of  Immunoprophylaxis” of the Ministry of Health and Social Protection of Population of the Republic of Tajikistan

State Educational Establishment “Avicenna Tajik State Medical University” of the Ministry of Health and Social Protection of Population of the Republic of Tajikistan

Aim. Study of the world experience in the vaccine against HPV introduction and determining the acceptability of its introduc- tion in Tajikistan.

Material and methods. Explored all available materials from the World Health Organization’s Regional Office for Europe on human papillomavirus (HPV), proceedings of the WHO Regional Training Workshop on strengthening the decision-making

system in the area of evidence-based immunization (Copenhagen, Denmark, May 14-17, 2018), as well as a review of published articles on the effectiveness of HPV prevention, the epidemiological situation of HPV and the experience of HPV vaccine intro- duction.

Results. The article presents a general description of HPV and its influence on the development of cervical cancer. The list of diseases caused by different types of HPV is reflected. Revealed that cervical cancer is the fourth most common type of cancer in women around the world. In 2012, 530 000 new cases of the disease were reported. This kind is the cause of 7,5% of all deaths of women from cancer. WHO estimates that more than out of 270 000 annual deaths from cervical cancer 85% occur in least developed countries. This disease can be prevented by introducing the HPV vaccine, since only 16 and 18 types of HPV cause 70% of cervical cancers.

Conclusion. The study of vaccine against HPV introduction significantly affects the epidemiological situation of development of cervical cancer in reproductive women. Recommend the National Technical Advisory Group on Immunization to study the introduction of HPV vaccine in the National immunization calendar.

Key words: cervical cancer, HPV vaccine, recommendations for implementation in Tajikistan


  1. Vaktsiny protiv virusa papillomy cheloveka: dokument po pozitsii VOZ, № 19 [WHO. Vaccines against human papillomavirus: WHO position paper, No. 19]. Zheneva, 2017; 92, 241-268.
  2. Virus papillomy cheloveka (VPCH) i rak sheyki matki [WHO. Human papillomavirus (HPV) and cervical cancer]. Available on: http://www.who.int/ru/ news-room/fact-sheets/detail/human-papillomavirus-(h- pv)-and-cervical-cancer
  3. Lysenko V., Ziganshin O. R., Shevchenko S. Yu. Papillomavirusnaya infektsiya u semeynykh par [Pap- illomavirus infection in couples]. Vestnik dermatologii i venerologii – Bulletin of dermatology and venereology, 2016; 4: 42-48.
  4. Narvskaya V. Virus papillomy cheloveka: ep- idemiologiya, laboratornaya diagnostika i profi papillomavirusnoy infektsii [Human papillomavirus: epidemiology, laboratory diagnosis and prevention of papillomavirus infection]. Infektsiya i immunitet – Infection and immunity, 2011; 1(1): 15–22
  5. Spetsialisty o privivkakh [Specialists about vacci- nations]. Available on: http://www.yaprivit.ru/diseases/ virus-papillomy-cheloveka/.
  6. Shakhtakhtinskaya Ch., Namazova-Baranova L. S., Tatochenko V. K., Novikova D. A., Tkachenko N. E. Virus papillomy cheloveka. Profilaktika VPCH-assotsiiro- vannykh zabolevaniy. Vaktsinatsiya v sovremennom mire [Human papilloma virus. Prevention of HPV-associated diseases. Vaccination in the modern world]. Pediatricheskaya farmakologiya – Pediatric pharmacology, 2015; 1(1): 74-78
  7. Chaturvedi , Maura L. Gillison. Human Papil- lomavirus and Head and Neck Cancer. Epidemiology, Pathogenesis and Prevention of Head and Neck Cancer. New York, Springer, 2010; 33: 3235-3242/
  8. Jemal , Simard E. P., Dorell C., Annual report to the nation on the status of cancer, 1975- 2009, featuring the burden and trends in human papillomavirus (HPV)-associ- ated cancers and HPV vaccination coverage levels. J. Natl. Cancer. Inst., 2013; 105: 175-201.
  9. Marais , Gawarecki D., Allan B., Ahmed K., Altini
  10. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papilloma- virus infection. Antiviral Therapy, 2011; 16(8): 1219–1226.

Information about authors:

Mirzoev Azamdzhon Safolovich – Head of the Department of Epidemiology, Hygiene and En- vironmental Protection of the State Educational Establishment “Institute of Postgraduate Educa- tion in Healthcare of the Republic of Tajikistan”, Candidate of Medical Sciences, tel.: +992 907 70 98 72; e-mail: azamdjon@mail.ru

Nazurdinov Anvar Bakhtierovich – Deputy Di- rector of the State Establishment “Republican Center of Immunoprophylaxis” of the Ministry of Health and Social Protection of Population of the Republic of Tajikistan

Pages: 180-187

Download the article

Scroll Up